# Jupiter Life Line Hospitals (NSE: JLHL) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/JLHL · Pivot · prices to 22 Oct 2026

Jupiter Life Line Hospitals (NSE: JLHL) closed at ₹244.75 on 22 Oct 2026, down 0.87% on the day. With a market capitalisation of ₹1,605 Cr, it ranks 1230th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Medical Care Facilities.

At its last close the stock traded at 8.3× trailing earnings, against a return on equity of 12.6% in FY26. Over the past year the share price has fallen 20.0%. Its 52-week range is ₹234.95 (15 Oct 2026) to ₹340.00 (30 Jul 2026); the last close is 28.0% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹411 Cr (+18.2% year on year) and net profit ₹38 Cr (−14.5%), on a consolidated basis. Promoters held 40.91% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹244.75 |
| Market cap | ₹1,605 Cr |
| P/E (trailing) | 8.3 |
| ROE | 12.6% (FY26) |
| ROCE | 13.8% (FY26) |
| Debt to equity | 0.33 |
| 52-week high | ₹340.00 (30 Jul 2026) |
| 52-week low | ₹234.95 (15 Oct 2026) |
| 1-year return | −20.0% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY27 | ₹411 Cr | +18.2% | ₹38 Cr | −14.5% | ₹5.72 |
| Q4 FY26 | ₹388 Cr | +18.7% | ₹50 Cr | +12.0% | ₹7.66 |
| Q3 FY26 | ₹365 Cr | +14.0% | ₹43 Cr | −19.1% | ₹6.49 |
| Q2 FY26 | ₹394 Cr | +22.0% | ₹57 Cr | +11.6% | ₹8.75 |
| Q1 FY26 | ₹348 Cr | +21.1% | ₹44 Cr | −1.6% | ₹6.69 |
| Q4 FY25 | ₹327 Cr | +12.5% | ₹45 Cr | −0.9% | ₹6.84 |
| Q3 FY25 | ₹321 Cr | +17.6% | ₹53 Cr | +20.2% | ₹8.01 |
| Q2 FY25 | ₹323 Cr | +22.6% | ₹52 Cr | +52.9% | ₹7.86 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹1,262 Cr | ₹194 Cr |
| FY24 | ₹1,070 Cr | ₹177 Cr |
| FY23 | ₹893 Cr | ₹73 Cr |
| FY22 | ₹733 Cr | ₹51 Cr |
| FY21 | ₹486 Cr | −₹2 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 40.91%
- Foreign institutions: 9.37%
- Domestic institutions: 16.51%
- Non-institutions: 33.21%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Titan Biotech](https://app.pivotnow.in/stock/TITANBIO) | — | ₹1,793 Cr | — | — |
| [Fischer Medical Ventures](https://app.pivotnow.in/stock/FISCHER) | ₹26.21 | ₹1,715 Cr | 58.2 | — |
| [NGL Fine-Chem](https://app.pivotnow.in/stock/NGLFINE) | ₹2,717.20 | ₹1,679 Cr | 34.8 | — |
| [Krsnaa Diagnostics](https://app.pivotnow.in/stock/KRSNAA) | ₹510.75 | ₹1,657 Cr | 16.5 | — |
| [Astec LifeSciences](https://app.pivotnow.in/stock/ASTEC) | ₹700.20 | ₹1,560 Cr | — | — |
| [Suraksha Diagnostic](https://app.pivotnow.in/stock/SURAKSHA) | ₹294.05 | ₹1,531 Cr | 47.6 | — |

## Questions and answers

### What is the share price of Jupiter Life Line Hospitals today?

Jupiter Life Line Hospitals (NSE: JLHL) last closed at ₹244.75 on 22 Oct 2026. Its 52-week high is ₹340.00 and its 52-week low is ₹234.95.

### What is the market cap of Jupiter Life Line Hospitals?

Jupiter Life Line Hospitals' market capitalisation is ₹1,605 Cr (₹1,605 Cr) at the 22 Oct 2026 close, ranking 1230th among the NSE companies Pivot tracks.

### What is the P/E ratio of Jupiter Life Line Hospitals?

Jupiter Life Line Hospitals trades at a trailing P/E of 8.3. The median P/E of the 4 closest Pharma & Healthcare peers by market cap is 47.6.

### What is the ROE and ROCE of Jupiter Life Line Hospitals?

Return on equity was 12.6% in FY26 and return on capital employed was 13.8% in FY26 (consolidated figures).

### Is Jupiter Life Line Hospitals a debt-free company?

No. Jupiter Life Line Hospitals' debt-to-equity ratio was 0.33 in FY26, with total debt of ₹501 Cr.

### What were Jupiter Life Line Hospitals' latest quarterly results?

For Q1 FY27 (quarter ended 30 Jun 2026), Jupiter Life Line Hospitals reported revenue of ₹411 Cr, +18.2% year on year, and net profit of ₹38 Cr, −14.5% year on year.

### How has Jupiter Life Line Hospitals stock performed over the last year?

Jupiter Life Line Hospitals' share price has fallen 20.0% over the past year, −21.8% over three months and −10.4% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Jupiter Life Line Hospitals?

As of 30 Jun 2026: promoters 40.91%, foreign institutions 9.37%, domestic institutions 16.51%, non-institutions 33.21%.

### Who are Jupiter Life Line Hospitals' competitors?

The listed Pharma & Healthcare companies closest to Jupiter Life Line Hospitals by market cap are Titan Biotech, Fischer Medical Ventures, NGL Fine-Chem, Krsnaa Diagnostics, Astec LifeSciences and Suraksha Diagnostic.

### Is Jupiter Life Line Hospitals a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Jupiter Life Line Hospitals' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on JLHL against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.